Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15.
Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15.
Humacyte的股票在公司宣佈SYMVESS獲得FDA批准用於治療肢體血管損傷後，交易價格上漲。HC Wainwright & Co.將該股票的目標價格從12美元上調至15美元。
Humacyte Shares Are Trading Higher After the Company Announced FDA Approval for SYMVESS for Treating Extremity Vascular Injuries. HC Wainwright & Co. Raised Its Price Target on the Stock From $12 to $15.
Humacyte的股票在公司宣佈SYMVESS獲得FDA批准用於治療肢體血管損傷後，交易價格上漲。HC Wainwright & Co.將該股票的目標價格從12美元上調至15美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間